These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20799471)

  • 1. Clinical trials with recombinant allergens--three perspectives: industry.
    Narkus A; Kniest F; Menzel A; Meyer H; Sprung V
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():270-5; discussion 275-8. PubMed ID: 20799471
    [No Abstract]   [Full Text] [Related]  

  • 2. Sublingual immunotherapy: allergen specific or placebo effect?
    Kette F; Smith W
    J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience with recombinant molecules for allergy vaccination.
    Cromwell O; Niederberger V; Horak F; Fiebig H
    Curr Top Microbiol Immunol; 2011; 352():27-42. PubMed ID: 21562972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of recombinant allergens for immunotherapy.
    Pauli G; Malling HJ
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):575-81. PubMed ID: 20859201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.
    Niggemann B; Jacobsen L; Dreborg S; Ferdousi HA; Halken S; Høst A; Koivikko A; Koller D; Norberg LA; Urbanek R; Valovirta E; Wahn U; Möller C;
    Allergy; 2006 Jul; 61(7):855-9. PubMed ID: 16792584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children.
    Dehlink E; Eiwegger T; Gerstmayr M; Kampl E; Bohle B; Chen KW; Vrtala S; Urbanek R; Szépfalusi Z
    Clin Exp Allergy; 2006 Jan; 36(1):32-9. PubMed ID: 16393263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving pollen immunotherapy: minor allergens and panallergens.
    Moreno-Aguilar C
    Allergol Immunopathol (Madr); 2008; 36(1):26-30. PubMed ID: 18261430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
    Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
    Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.
    Jacobsen L; Niggemann B; Dreborg S; Ferdousi HA; Halken S; Høst A; Koivikko A; Norberg LA; Valovirta E; Wahn U; Möller C;
    Allergy; 2007 Aug; 62(8):943-8. PubMed ID: 17620073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of recombinant allergens.
    Cromwell O; Narkus A
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):195-200; discussion 200-3. PubMed ID: 17393740
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber.
    Meyer W; Narkus A; Salapatek AM; Häfner D
    Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study.
    Marogna M; Spadolini I; Massolo A; Canonica GW; Passalacqua G
    J Allergy Clin Immunol; 2005 Jun; 115(6):1184-8. PubMed ID: 15940132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-short-course booster allergen immunotherapy.
    Pfaar O; Pieper-Fürst U; Mösges R
    Immunotherapy; 2018 Jun; 10(7):525-528. PubMed ID: 29562789
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergen-specific immunotherapy with recombinant allergens.
    Pauli G; Malling HJ
    Curr Top Microbiol Immunol; 2011; 352():43-54. PubMed ID: 21404096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pollinex Parietaria (Bencard Parietaria), a new allergoid for treatment of patients sensitive to Parietaria pollen.
    Resta O; Carnimeo N; Foschino MP; Taylor I; Wheeler AW; Youlten LJ
    J Investig Allergol Clin Immunol; 1991 Apr; 1(2):129-37. PubMed ID: 1669569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study.
    Allam JP; Wuestenberg E; Wolf H; Klimek L; Decot E; Horn A; Schnitker J; Bieber T; Novak N
    J Allergy Clin Immunol; 2014 Jun; 133(6):1757-9.e3. PubMed ID: 24794686
    [No Abstract]   [Full Text] [Related]  

  • 19. Allergen immunotherapy for birch-apple syndrome: what do we know?
    Incorvaia C; Ridolo E; Mauro M; Russello M; Pastorello E
    Immunotherapy; 2017 Nov; 9(15):1271-1278. PubMed ID: 29130794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria).
    Bonifazi F; Antonicelli L; Bilò MB; Pucci S; Taylor IH; Wheeler AW; Youlten LJ
    J Investig Allergol Clin Immunol; 1991 Feb; 1(1):37-44. PubMed ID: 1669563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.